Novartis Cuts 322 Jobs at East Hanover HQ in Fourth Round of Restructuring

Novartis announced a fourth round of workforce reductions at its East Hanover, New Jersey headquarters, with a WARN filing showing 322 positions to be eliminated effective October 2, 2026. These latest cuts bring the total planned job losses at the site to 572 this year, following earlier rounds that eliminated 114, 76 and 60 roles tied to rare disease sales, biomedical research and US field sales teams. The company said the restructuring affects field sales, patient support and marketing as it reorganises commercial functions in response to changing market conditions and patent expiries on key medicines including Tasigna, Promacta and Entresto. Novartis framed the reductions as efforts to enhance operational efficiency and align resources with evolving patient, customer and business needs as part of a multi-year transformation.

Novartis East Hanover cut 322 jobs in NJ affecting its commercial (field sales, patient support and marketing) and broader commercial functions team as of October 2, 2026.

That is roughly 0.3% of the 110,000 people Novartis East Hanover employs.

LayoffTalk has tracked 24 layoff events at Novartis East Hanover since March 2025, including 234 jobs documented in official WARN filings, with 20 additional events known from news reporting.